We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DSSA:IDXPT Dian Swastatika Sentosa Tbk Analysis

Data as of 2026-03-11 - not real-time

IDR 77,750.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

PT Dian Swastatika Sentosa trades at IDR 77,750, which is far above its DCF‑derived fair value and reflects a PE of roughly 115× versus an industry average of 20×, and an astronomically high price‑to‑book ratio. These valuation gaps suggest the stock is significantly overvalued.
Technical indicators reinforce a bearish outlook: the price sits below the 20‑day (IDR 83,860) and 50‑day (IDR 93,943) moving averages, RSI is near 38 indicating modest oversold conditions, and the MACD histogram is negative, signaling downward momentum. Volume is increasing but volatility remains elevated at nearly 79% over the past 30 days, implying price swings could be sharp.
Fundamentally, revenue has contracted by 3.5% YoY, free cash flow is negative, and the company carries a debt‑to‑equity ratio of 66.7%, while offering no dividend. Although ROE sits at a respectable 18.5% and operating margins are in the low‑double‑digit range, the cash‑burn and lack of dividend sustainability weaken the investment case. Given the overvaluation, bearish technical setup, and cash flow concerns, the stock appears better suited for reduction rather than accumulation.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below key moving averages
  • Bearish MACD and RSI near oversold
  • Extreme overvaluation relative to peers

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential price correction toward support
  • Continued cash‑flow pressure
  • Sector transition risk in coal

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Structural decline in thermal coal demand
  • High valuation without dividend yield
  • Elevated regulatory and ESG headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth-3.50%
Profit Margin8.68%
P/E Ratio115.2
ROE18.53%
ROA6.26%
Debt/Equity66.74
P/B Ratio269965.3
Op. Cash FlowIDR337.4M
Free Cash FlowIDR-263177408
Industry P/E20.3

Technical Analysis

TrendNeutral
RSI37.9
SupportIDR 69,125.00
ResistanceIDR 98,000.00
MA 20IDR 83,860.00
MA 50IDR 93,943.50
MA 200IDR 87,494.88
MACDBearish
VolumeIncreasing
Fear & Greed Index75.86

Valuation

Fair ValueIDR 0.41
Target PriceIDR 150,000.00
Upside/Downside92.93%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.18
Volatility78.75%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.